CRWV has fallen 56.9 percent over twelve months while the S&P 500 gained 17.4 percent, and shares trade near yearly lows at $61.12. Yet the disconnect between valuation and fundamentals is now the investment question.
The stock trades at 4.4 times last twelve months revenue, down sharply from 18.9 times a year ago. Over that period, CoreWeave's operating margin swung from positive 6.3 percent to negative 3.0 percent—a red flag that revenue growth is not translating to profitability.
The cash flow picture muddies the bear case. CoreWeave generated $6.9 billion in operating cash flow over twelve months, yet free cash flow was negative $13.7 billion due to massive infrastructure buildout. Total debt now stands at 153.2 percent of market value, against an S&P 500 average of 20.0 percent. That leverage is unsustainable if the company cannot reach positive free cash flow.
What lifts the bull thesis: CoreWeave's $104.2 billion revenue backlog as of June represents a 246 percent year-over-year increase. Management disclosed this on an August 11 earnings call. In July, the company raised prices approximately 25 percent across its product suite and stated that near-term capacity is effectively sold out following the increase.
For full-year fiscal 2026, management raised revenue guidance to $12.4 billion to $13.2 billion. The catalyst arrives in November. CoreWeave reports Q3 fiscal 2026 results (for the July-to-September quarter ending Sept. 30) around Nov. 11. Analysts project $3.62 billion in quarterly revenue. Management's own guidance for the quarter is $3.45 billion to $3.6 billion.
Q3 revenue of $2.58 billion in the prior quarter means the July price increases must drive material growth for the stock to move. A miss below $3.45 billion invalidates the bull case and makes buying at $61 premature. Revenue within management's guide but below the $3.62 billion analyst consensus leaves the waiting case intact—the stock needs a beat.
The decisive catalyst: Q3 revenue above $3.62 billion paired with another full-year guidance raise. That combination ends the thesis of waiting. Anything less and the leverage-to-debt burden and path to positive free cash flow remain unproven. Investors have a specific hurdle to watch on Nov. 11.
